 |
|
|
| |
DOLUTEGRAVIR USE IS ASSOCIATED WITH HIGHER POSTPARTUM WEIGHT COMPARED TO EFAVIRENZ
|
| |
| |
CROI 2020
Reported by Jules Levin
Jennifer Jao,1,4Shan Sun,2Justine Legbedze,2Denise L. Jacobson,3Keolebogile Mmasa,4Samuel Kgole,4Gosego Masasa,4Joseph Makhema,4Sikhulile Moyo,4Mompati Mmalane,4Francis
Banda,4Bornapate Nkomo,5Mariana Gerschenson,6Elaine J. Abrams,7and Kathleen M. Powis4,8,9
• Northwestern University Feinberg School of Medicine, Department of Pediatrics, Division of Pediatric Infectious Diseases, Department of Medicine, Division of Adult Infectious Diseases, Chicago, IL, USA; • Ann and Robert H. Lurie Children's Hospital ofChicago, Department of Pediatrics, Chicago, IL, USA; • Harvard T.H. Chan School of Public Health, Department of Biostatistics, Center for Biostatistics in AIDS Research, Boston, MA, USA; ⁴Botswana Harvard AIDS Partnership, Gaborone, Botswana; 5 Ministry of Health and Wellness, Gaborone, Botswana; 6University of Hawaii at Manoa, Department of Cellular and Molecular Biology, Honolulu, HI, USA; ⁷ICAP at Columbia, Mailman School of Public Health, VagellosCollege of Physicians and Surgeons, Columbia University, New York, NY, USA; ⁸Massachusetts General Hospital, Department of Internal Medicine and Pediatrics, Boston, MA, USA; 9 Harvard T.H. Chan School of Public Health, Department of Immunology and Infectious Diseases, Boston, MA, USA
--------------------------
Predicted Rise in Diabetes Risk With TAF/FTC+DTG Versus TDF/FTC+DTG - (03/12/20)
The QDIABETES Equation (https://qdiabetes.org) rose significantly more with TAF/FTC+DTG than with TDF/FTC+DTG through 96 weeks (+0.90% versus +0.50%, P = 0.004). The ADVANCE team noted that these comparisons of MI and diabetes risk are limited because of the young age of the study population. They added that weight continued to rise through 96 weeks in women taking TAF/FTC+DTG, with no sign of a plateau, and the predictive models used did not account for additional weight gain after week 96. The investigators estimated that people randomized to TAF/FTC+DTG would have 3 more cases of diabetes per 1000 people than participants randomized to TDF/FTC+DTG. They urged colleagues to repeat these analyses in other trials and patient populations taking TAF/FTC plus an integrase inhibitor. In 2019 the World Health Organization revised its first-line antiretroviral guidelines, making the first choice TDF/(FTC or 3TC) + DTG [2]. TAF "may be considered [in first-line regimens] for patients with established osteoporosis and/or impaired renal function."
----------------------
|
| |
|
|
|
|
|
